Annual Total Liabilities
$38.38 M
-$20.18 M-34.46%
December 31, 2023
Summary
- As of February 7, 2025, ABUS annual total liabilities is $38.38 million, with the most recent change of -$20.18 million (-34.46%) on December 31, 2023.
- During the last 3 years, ABUS annual total liabilities has risen by +$3.27 million (+9.31%).
- ABUS annual total liabilities is now -76.68% below its all-time high of $164.61 million, reached on December 31, 2015.
Performance
ABUS Total Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Total Liabilities
$33.55 M
-$4.04 M-10.74%
September 30, 2024
Summary
- As of February 7, 2025, ABUS quarterly total liabilities is $33.55 million, with the most recent change of -$4.04 million (-10.74%) on September 30, 2024.
- Over the past year, ABUS quarterly total liabilities has dropped by -$2.10 million (-5.90%).
- ABUS quarterly total liabilities is now -82.65% below its all-time high of $193.37 million, reached on March 31, 2015.
Performance
ABUS Quarterly Total Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Total Liabilities Formula
Total Liabilities = Current Liabilities + Long-Term Liabilities
ABUS Total Liabilities Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -34.5% | -5.9% |
| 3 y3 years | +9.3% | -42.7% |
| 5 y5 years | +38.7% | -42.7% |
ABUS Total Liabilities Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -34.5% | +9.5% | -52.8% | at low |
| 5 y | 5-year | -34.5% | +17.1% | -52.8% | +14.3% |
| alltime | all time | -76.7% | +2632.1% | -82.7% | +727.8% |
Arbutus Biopharma Total Liabilities History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | - | $33.55 M(-10.7%) |
| Jun 2024 | - | $37.59 M(+5.4%) |
| Mar 2024 | - | $35.65 M(-7.1%) |
| Dec 2023 | $38.38 M(-34.5%) | $38.38 M(-2.3%) |
| Sep 2023 | - | $39.30 M(-6.7%) |
| Jun 2023 | - | $42.13 M(-10.9%) |
| Mar 2023 | - | $47.31 M(-19.2%) |
| Dec 2022 | $58.57 M(+67.1%) | $58.57 M(+0.5%) |
| Sep 2022 | - | $58.28 M(-7.0%) |
| Jun 2022 | - | $62.69 M(-11.7%) |
| Mar 2022 | - | $71.03 M(+102.7%) |
| Dec 2021 | $35.05 M(-0.2%) | $35.05 M(-1.2%) |
| Sep 2021 | - | $35.46 M(+2.6%) |
| Jun 2021 | - | $34.55 M(+7.7%) |
| Mar 2021 | - | $32.09 M(-8.6%) |
| Dec 2020 | $35.11 M(+7.1%) | $35.11 M(+4.0%) |
| Sep 2020 | - | $33.76 M(+5.1%) |
| Jun 2020 | - | $32.11 M(+9.4%) |
| Mar 2020 | - | $29.36 M(-10.5%) |
| Dec 2019 | $32.79 M(+18.5%) | $32.79 M(-2.5%) |
| Sep 2019 | - | $33.64 M(+19.7%) |
| Jun 2019 | - | $28.10 M(+0.3%) |
| Mar 2019 | - | $28.01 M(+1.2%) |
| Dec 2018 | $27.67 M(-49.4%) | $27.67 M(-8.2%) |
| Sep 2018 | - | $30.15 M(-22.6%) |
| Jun 2018 | - | $38.94 M(+3.5%) |
| Mar 2018 | - | $37.61 M(-31.2%) |
| Dec 2017 | $54.69 M(-25.0%) | $54.69 M(-24.5%) |
| Sep 2017 | - | $72.45 M(-8.6%) |
| Jun 2017 | - | $79.29 M(+0.3%) |
| Mar 2017 | - | $79.04 M(+8.4%) |
| Dec 2016 | $72.91 M(-55.7%) | $72.91 M(-25.7%) |
| Sep 2016 | - | $98.11 M(-1.4%) |
| Jun 2016 | - | $99.54 M(-39.7%) |
| Mar 2016 | - | $165.18 M(+0.3%) |
| Dec 2015 | $164.61 M(+446.1%) | $164.61 M(-2.5%) |
| Sep 2015 | - | $168.82 M(-8.9%) |
| Jun 2015 | - | $185.32 M(-4.2%) |
| Mar 2015 | - | $193.37 M(+541.5%) |
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2014 | $30.14 M(+140.7%) | $30.14 M(+2.0%) |
| Sep 2014 | - | $29.56 M(+9.8%) |
| Jun 2014 | - | $26.92 M(-18.5%) |
| Mar 2014 | - | $33.04 M(+163.8%) |
| Dec 2013 | $12.52 M(+7.2%) | $12.52 M(-7.5%) |
| Sep 2013 | - | $13.54 M(+13.9%) |
| Jun 2013 | - | $11.89 M(-5.8%) |
| Mar 2013 | - | $12.63 M(+8.2%) |
| Dec 2012 | $11.68 M(+37.4%) | $11.68 M(+17.0%) |
| Sep 2012 | - | $9.98 M(+23.3%) |
| Jun 2012 | - | $8.09 M(-13.1%) |
| Mar 2012 | - | $9.31 M(+9.5%) |
| Dec 2011 | $8.50 M(-17.4%) | $8.50 M(+3.5%) |
| Sep 2011 | - | $8.21 M(-22.7%) |
| Jun 2011 | - | $10.63 M(+12.4%) |
| Mar 2011 | - | $9.46 M(-8.0%) |
| Dec 2010 | $10.29 M(+58.0%) | $10.29 M(+6.3%) |
| Sep 2010 | - | $9.68 M(+22.0%) |
| Jun 2010 | - | $7.93 M(+71.4%) |
| Mar 2010 | - | $4.63 M(-28.9%) |
| Dec 2009 | $6.51 M(+60.6%) | $6.51 M(+2.7%) |
| Sep 2009 | - | $6.34 M(+25.0%) |
| Jun 2009 | - | $5.07 M(+16.1%) |
| Mar 2009 | - | $4.36 M(+7.7%) |
| Dec 2008 | $4.05 M(-37.3%) | $4.05 M(-26.5%) |
| Sep 2008 | - | $5.51 M(-30.5%) |
| Jun 2008 | - | $7.93 M(+60.9%) |
| Mar 2008 | - | $4.93 M(-23.7%) |
| Dec 2007 | $6.46 M(+9.9%) | $6.46 M(-18.7%) |
| Sep 2007 | - | $7.95 M(-19.5%) |
| Jun 2007 | - | $9.88 M |
| Dec 2006 | $5.88 M(-84.1%) | - |
| Dec 2005 | $36.99 M(-28.3%) | - |
| Dec 2004 | $51.60 M(+44.6%) | - |
| Dec 2003 | $35.68 M(+4.8%) | - |
| Dec 2002 | $34.05 M(+456.5%) | - |
| Dec 2001 | $6.12 M(+145.2%) | - |
| Dec 2000 | $2.49 M(+29.9%) | - |
| Dec 1999 | $1.92 M(+36.7%) | - |
| Dec 1998 | $1.40 M | - |
FAQ
- What is Arbutus Biopharma annual total liabilities?
- What is the all time high annual total liabilities for Arbutus Biopharma?
- What is Arbutus Biopharma annual total liabilities year-on-year change?
- What is Arbutus Biopharma quarterly total liabilities?
- What is the all time high quarterly total liabilities for Arbutus Biopharma?
- What is Arbutus Biopharma quarterly total liabilities year-on-year change?
What is Arbutus Biopharma annual total liabilities?
The current annual total liabilities of ABUS is $38.38 M
What is the all time high annual total liabilities for Arbutus Biopharma?
Arbutus Biopharma all-time high annual total liabilities is $164.61 M
What is Arbutus Biopharma annual total liabilities year-on-year change?
Over the past year, ABUS annual total liabilities has changed by -$20.18 M (-34.46%)
What is Arbutus Biopharma quarterly total liabilities?
The current quarterly total liabilities of ABUS is $33.55 M
What is the all time high quarterly total liabilities for Arbutus Biopharma?
Arbutus Biopharma all-time high quarterly total liabilities is $193.37 M
What is Arbutus Biopharma quarterly total liabilities year-on-year change?
Over the past year, ABUS quarterly total liabilities has changed by -$2.10 M (-5.90%)